4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $33.25.

Several research firms have commented on FDMT. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Leerink Partners restated an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st.

4D Molecular Therapeutics Trading Down 2.1%

Shares of NASDAQ:FDMT opened at $9.29 on Thursday. The stock has a market cap of $530.74 million, a PE ratio of -2.48 and a beta of 3.01. The stock’s fifty day simple moving average is $8.88 and its two-hundred day simple moving average is $8.41. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. On average, sell-side analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Wexford Capital LP bought a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. Los Angeles Capital Management LLC purchased a new stake in 4D Molecular Therapeutics during the second quarter valued at about $42,000. Quadrature Capital Ltd bought a new position in 4D Molecular Therapeutics during the second quarter worth about $42,000. Finally, Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.